lung cancer
Conditions
Interventions
experimental group:Feiyanning prescription + Gefitinib
control group:Gefitinib + placebo
Sponsors
Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with stage III-IV lung adenocarcinoma by pathology or cytology, or those with postoperative recurrence and metastasis; (2) EGFR detection sensitive type (with mutations in exons 18, 19, and 21, and no mutation in exon 20); (3) Those who meet the criteria of traditional Chinese medicine syndrome types; (4) Patients aged over 18 years and <= 75 years old; (5) Physical fitness score <= 2 points; (6) Normal range of blood count, heart, liver, and kidney function; (7) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Other tumor history within 5 years; (2) EGFR detected sensitive type (20 exon mutations); (3) Expected survival< 3 months; (4) Patients with severe liver, liver, and kidney diseases; (5)Patients during pregnancy or lactation; (6) Persons with a history of mental illness. (7) Patients who are currently participating in other drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate;duration of disease control;The quality of life;TCM clinical syndromes and symptoms;Serum tumor markers;Lymphocyte subtype;Safety index; | — |
Countries
China
Contacts
Public ContactWang Zhongqi
Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed